Checkpoint inhibitor-related renal vasculitis and use of rituximab

The percentage of patients with cancer eligible for checkpoint inhibitor (CPI) therapy has increased rapidly over the past few years and approaches 45%. As a result, more cases of CPI-related nephrotoxicity, including a rare subset with vasculitis, are being reported. To elucidate the clinical prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamlouk, Omar, Lin, Jamie S, Abdelrahim, Maen, Tchakarov, Amanda S, Glass, William F, Selamet, Umut, Buni, Maryam, Abdel-Wahab, Noha, Abudayyeh, Ala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380836/
https://www.ncbi.nlm.nih.gov/pubmed/32718987
http://dx.doi.org/10.1136/jitc-2020-000750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380836/
https://www.ncbi.nlm.nih.gov/pubmed/32718987
http://dx.doi.org/10.1136/jitc-2020-000750

Ejemplares similares